• Does a PNPLA3 Polymorphism Promote Fibrosis Progression in Patients with Hepatitis C?

Does a PNPLA3 Polymorphism Promote Fibrosis Progression in Patients with Hepatitis C?

A single nucleotide polymorphism (SNP) in the patatin-like phospholipase domain containing 3 gene (PNPLA3) is associated with baseline level of fibrosis and its progression, but not development of hepatocellular carcinoma (HCC), in patients with hepatitis C virus (HCV) infection, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Most

Read more
  • A Nanoparticle-based Approach to Selectively Target Hepatocellular Carcinomas

A Nanoparticle-based Approach to Selectively Target Hepatocellular Carcinomas

Researchers have created nanoparticles that selectively kill hepatoma cells and reduce growth of liver tumors in rats, they report in the February issue of Gastroenterology. They show that the particles induce tumor-specific necrosis by selectively disrupting redox balance within cancer cells. Dietary intake of the natural omega-3 fatty acid docosahexaenoic

Read more

Podcast: How Does Fatty Liver Affect Risk for Cardiovascular Disease?

Modification of risk factors for cardiovascular disease—particularly dyslipidemia—is required to reduce morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). In a Perspective article published in the July issue of Clinical Gastroenterology and Hepatology, Kathleen E. Corey and Naga Chalasani discuss the increased risk of cardiovascular disease among patients with NAFLD, and strategies

Read more

A New Drug for Diabetes and Fatty Liver Disease?

Obeticholic acid (OCA)—an agonist of the farnesoid X receptor (FXR)— increases insulin sensitivity and reduces markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), according to a study published in the September issue of Gastroenterology. Type 2 diabetes mellitus and

Read more